Saturday, February 22nd, 2014
Nuvilex, Inc.’s (NVLX) Expects to Continue Success of Cell-in-a-Box
Nuvilex, Inc.’s (NVLX) Expects to Continue Success of Cell-in-a-Box Technology with Marijuana-Based Treatments If Nuvilex, Inc. (OTCQB: NVLX) can use the Cell-in-a-Box™ technology to develop marijuana-based treatments for cancer with the same success it has seen in two independent clinical trials to develop a treatment for advanced inoperable pancreatic cancer, then the Cannabis industry is in for some real fireworks. Last week Nuvilex announced it will, in fact, use the unique and proprietary cellulose-based live-cell encapsulation technology, Cell-in-a-Box, to develop treatments for serious and deadly forms of cancer. In theRead More
Nuvilex Announces $27 Million Funding
Nuvilex Inc. (OTCQB: NVLX) Nuvilex Announces $27 Million Funding Commitment With Institutional Investor to Advance Late Phase Clinical Trials Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a Chicago-based institutional investor. Lincoln Park initially purchased 8 million shares of Nuvilex’s common stock at $0.25 per share for $2 million and has committed to invest, at the sole option of Nuvilex,Read More